Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:47:15.177Z.
Calculation as of: 2026-10-06T18:47:15.177Z.
Quote observation: 2026-10-06T18:45:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$535.16M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$561.59M
EBITDA Yield
N/A
TTM Avg
31.68%
3Y Avg
26.65%
5Y Avg
26.65%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $546.91M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $538.63M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $535.63M | N/A | 1.23% | 1.23% | 1.23% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $534.18M | N/A | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | N/A | N/A | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $535.16M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $561.59M | N/A | 31.68% | 26.65% | 26.65% |
| CorMedix Inc. (CRMD)vs › | $569.18M | 55.09% | 22.76% | 17.21% | 17.21% |
| Immix Biopharma, Inc. (IMMX)vs › | $523.62M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
